CA2351075A1 - Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications - Google Patents
Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications Download PDFInfo
- Publication number
- CA2351075A1 CA2351075A1 CA002351075A CA2351075A CA2351075A1 CA 2351075 A1 CA2351075 A1 CA 2351075A1 CA 002351075 A CA002351075 A CA 002351075A CA 2351075 A CA2351075 A CA 2351075A CA 2351075 A1 CA2351075 A1 CA 2351075A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- oxoethyl
- acceptable salt
- pyridinium bromide
- aminocarbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 15
- 230000032683 aging Effects 0.000 title claims abstract description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 230000002792 vascular Effects 0.000 title claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 63
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 8
- 208000002249 Diabetes Complications Diseases 0.000 claims abstract description 8
- 208000017442 Retinal disease Diseases 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 8
- 208000017169 kidney disease Diseases 0.000 claims abstract description 8
- 208000028389 Nerve injury Diseases 0.000 claims abstract description 7
- 206010038923 Retinopathy Diseases 0.000 claims abstract description 7
- 238000002845 discoloration Methods 0.000 claims abstract description 7
- 230000008764 nerve damage Effects 0.000 claims abstract description 7
- 230000003178 anti-diabetic effect Effects 0.000 claims abstract description 5
- 239000003472 antidiabetic agent Substances 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- -1 -Oalkyl Chemical group 0.000 claims description 28
- BBFCIBZLAVOLCF-UHFFFAOYSA-N pyridin-1-ium;bromide Chemical compound Br.C1=CC=NC=C1 BBFCIBZLAVOLCF-UHFFFAOYSA-N 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 206010012655 Diabetic complications Diseases 0.000 claims description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
- 206010062198 microangiopathy Diseases 0.000 claims description 5
- 230000004768 organ dysfunction Effects 0.000 claims description 5
- 150000003222 pyridines Chemical class 0.000 claims description 5
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 4
- ZPMGJNQUSYNXAV-UHFFFAOYSA-N butyl 1-(2-anilino-2-oxoethyl)pyridin-1-ium-3-carboxylate;chloride Chemical compound [Cl-].CCCCOC(=O)C1=CC=C[N+](CC(=O)NC=2C=CC=CC=2)=C1 ZPMGJNQUSYNXAV-UHFFFAOYSA-N 0.000 claims description 4
- 230000008694 endothelial dysfunction Effects 0.000 claims description 4
- JJPCPHMZUOFGRD-UHFFFAOYSA-N n-butyl-1-[2-(2,4-dichlorophenyl)-2-oxoethyl]pyridin-1-ium-3-carboxamide;bromide Chemical compound [Br-].CCCCNC(=O)C1=CC=C[N+](CC(=O)C=2C(=CC(Cl)=CC=2)Cl)=C1 JJPCPHMZUOFGRD-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- DADJMTZDNBKVQT-UHFFFAOYSA-M 2-(3-benzoylpyridin-1-ium-1-yl)-1-phenylethanone;bromide Chemical compound [Br-].C=1C=CC=CC=1C(=O)C[N+](C=1)=CC=CC=1C(=O)C1=CC=CC=C1 DADJMTZDNBKVQT-UHFFFAOYSA-M 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- HEBZOWPEXHXCJQ-UHFFFAOYSA-M butyl 1-[2-(2,4-dichlorophenyl)-2-oxoethyl]pyridin-1-ium-3-carboxylate;bromide Chemical compound [Br-].CCCCOC(=O)C1=CC=C[N+](CC(=O)C=2C(=CC(Cl)=CC=2)Cl)=C1 HEBZOWPEXHXCJQ-UHFFFAOYSA-M 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- CBQHPQSLJHFWSK-UHFFFAOYSA-N ethyl 2-[3-(2-hydroxyethylcarbamoyl)pyridin-1-ium-1-yl]acetate;bromide Chemical compound [Br-].CCOC(=O)C[N+]1=CC=CC(C(=O)NCCO)=C1 CBQHPQSLJHFWSK-UHFFFAOYSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- CKXHCIGYEMYBFL-UHFFFAOYSA-M methyl 1-phenacylpyridin-1-ium-3-carboxylate;bromide Chemical compound [Br-].COC(=O)C1=CC=C[N+](CC(=O)C=2C=CC=CC=2)=C1 CKXHCIGYEMYBFL-UHFFFAOYSA-M 0.000 claims description 3
- 210000000214 mouth Anatomy 0.000 claims description 3
- VIOBNLFICFEKRB-UHFFFAOYSA-N n-(2-hydroxyethyl)-1-phenacylpyridin-1-ium-3-carboxamide;bromide Chemical compound [Br-].OCCNC(=O)C1=CC=C[N+](CC(=O)C=2C=CC=CC=2)=C1 VIOBNLFICFEKRB-UHFFFAOYSA-N 0.000 claims description 3
- CIXPPOWOBNYQAD-UHFFFAOYSA-N n-(4-methyl-1,3-thiazol-2-yl)-1-phenacylpyridin-1-ium-3-carboxamide;bromide Chemical compound [Br-].CC1=CSC(NC(=O)C=2C=[N+](CC(=O)C=3C=CC=CC=3)C=CC=2)=N1 CIXPPOWOBNYQAD-UHFFFAOYSA-N 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- QCVLYYNXACQGJF-UHFFFAOYSA-N 1-(2-anilino-2-oxoethyl)-n-(2-hydroxyethyl)pyridin-1-ium-3-carboxamide;chloride Chemical compound [Cl-].OCCNC(=O)C1=CC=C[N+](CC(=O)NC=2C=CC=CC=2)=C1 QCVLYYNXACQGJF-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-L Oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 229940051866 mouthwash Drugs 0.000 claims description 2
- QARTURCDVYEVIZ-UHFFFAOYSA-N n-(2,3,3a,4-tetrahydro-1,3-benzothiazol-2-yl)-1-[2-(2,4-dichlorophenyl)-2-oxoethyl]pyridin-1-ium-3-carboxamide;bromide Chemical compound [Br-].ClC1=CC(Cl)=CC=C1C(=O)C[N+]1=CC=CC(C(=O)NC2SC3=CC=CCC3N2)=C1 QARTURCDVYEVIZ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Chemical compound [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 2
- 229940085991 phosphate ion Drugs 0.000 claims description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 claims description 2
- 229940034610 toothpaste Drugs 0.000 claims description 2
- 239000000606 toothpaste Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- GHCXALOJXYUCCD-UHFFFAOYSA-N 1-(2-anilino-2-oxoethyl)-n-butylpyridin-1-ium-3-carboxamide;chloride Chemical compound [Cl-].CCCCNC(=O)C1=CC=C[N+](CC(=O)NC=2C=CC=CC=2)=C1 GHCXALOJXYUCCD-UHFFFAOYSA-N 0.000 claims 2
- QCWKWVVLPBTMKH-UHFFFAOYSA-N n-(2-hydroxyethyl)-1-(2-oxopropyl)pyridin-1-ium-3-carboxamide;bromide Chemical compound [Br-].CC(=O)C[N+]1=CC=CC(C(=O)NCCO)=C1 QCWKWVVLPBTMKH-UHFFFAOYSA-N 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 239000000644 isotonic solution Substances 0.000 claims 1
- 230000021368 organ growth Effects 0.000 claims 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims 1
- 238000005956 quaternization reaction Methods 0.000 claims 1
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 6
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- UJOUHMMIDLYDDD-UHFFFAOYSA-N 1-phenyl-2-(1,3-thiazol-3-ium-2-yl)ethanone;bromide Chemical compound [Br-].C=1C=CC=CC=1C(=O)CC1=[NH+]C=CS1 UJOUHMMIDLYDDD-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 108010055267 advanced glycation end products-bovine serum albumin Proteins 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- DASJDMQCPIDJIF-UHFFFAOYSA-N 2-bromo-1-(2,4-dichlorophenyl)ethanone Chemical compound ClC1=CC=C(C(=O)CBr)C(Cl)=C1 DASJDMQCPIDJIF-UHFFFAOYSA-N 0.000 description 2
- 101100328486 Caenorhabditis elegans cni-1 gene Proteins 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WEPWEAAPUYWSRR-UHFFFAOYSA-N n-(2-hydroxyethyl)-1-(2-oxopropyl)pyridin-1-ium-3-carboxamide;chloride Chemical compound [Cl-].CC(=O)C[N+]1=CC=CC(C(=O)NCCO)=C1 WEPWEAAPUYWSRR-UHFFFAOYSA-N 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 239000002687 nonaqueous vehicle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000011833 salt mixture Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 1
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- IMIDOCRTMDIQIJ-UHFFFAOYSA-N aminocarb Chemical compound CNC(=O)OC1=CC=C(N(C)C)C(C)=C1 IMIDOCRTMDIQIJ-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QQFYLZXBFWWJHR-UHFFFAOYSA-M benzyl(triethyl)phosphanium;bromide Chemical compound [Br-].CC[P+](CC)(CC)CC1=CC=CC=C1 QQFYLZXBFWWJHR-UHFFFAOYSA-M 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000012505 colouration Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- BTNXXHGEWCIWTR-UHFFFAOYSA-M propan-2-yl 1-phenacylpyridin-1-ium-3-carboxylate;bromide Chemical compound [Br-].CC(C)OC(=O)C1=CC=C[N+](CC(=O)C=2C=CC=CC=2)=C1 BTNXXHGEWCIWTR-UHFFFAOYSA-M 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
The invention discloses compounds of the pyridinium series useful for the management of diabetes and aging-related vascular complications, and particularly in the treatment of complications of diabetes mellitus and othe r aging-related conditions including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological conditions and discoloration of teeth by breaking preformed AGE, of general formula (I), or pharmaceutically acceptable salts thereof, wherein, R1, R2 and X are as defined in the specification. The invention also discloses method of preparation of the compounds of the series and pharmaceutical composition having one or more compounds as defined above as active ingredients. The invention further discloses a method of treatment of a diabetic patient by administering the compounds as defined above, either singly or in combination with other drugs for antidiabetic therapy.
Description
AND AGING-RELATED VASCULAR COMPLICATIONS
s to FIELD OF THE INVENTION
The present invention relates to a class of compounds of pyridinium series and to their use in treatment of diabetes and related illnesses. More particularly is the invention relates to compounds of this series, methods for their preparation, pharmaceutical composition containing these compounds and their use in the treatment of complications of diabetes mellitus. The compounds of this series exhibit AGE breaking activity, which is essential for the treatment of diabetic and aging-related complications including kidney disease, nerve damage, 2o atherosclerosis, retinopathy and dermatological conditions. The invention also extends to the method of reversing the discoloration of teeth resulting from nonenzymatic browning in the oral cavity which comprises administration of an amount effective to reverse pre-formed advanced glycosylation crosslinks.
BACKGROUND OF THE INVENTION
2s Maillard in 1912 found that reducing sugars, such as glucose and ribose react with proteins to form brown pigments. Further studies have shown that this is an irreversible non-enzymatic reaction, which occurs irl several natural systems including stored foodstuff. Maillard reaction occurs in two stages, early and s advanced. Initially, proteins react with glucose to form stable Amadori products, which subsequently cross-links to form advanced glycation end products (AGE).
In most cases, the formation of AGE also accompanies browning of the proteins and increase in the fluorescence.
In diabetes, where blood glucose level is significantly higher than normal, to the reaction of glucose with several proteins such as haemoglobin, lens crystallin and collagen, gives rise to the formation of AGE, which in turn, is responsible for the complications associated with diabetes, such as nephropathy, microangiopathy, endothelial dysfunction and other organ dysfunctions. In addition, the activity of several growth factors, such as basic fibroblast growth is factor, is also impaired. AGE products, unlike normal proteins in tissue, have a slower rate of turnover and replenishment. It has been reported that AGE
products may in fact elicit a complex immunological reaction involving RAGE
(Receptor for Advanced Glycation End Products) receptors and activation of several incompletely defined immunological processes. It has been documented 2o that diabetes with evidence of microangiopathy and macroangiopathy also show evidence of oxidative stress, the mechanism of which has not been elucidated.
in vitro AGE formation can be studied in the laboratory by incubating reducing sugars, such as ribose or glucose with bovine serum albumin. AGE
formation can be detected by increase in the fluorescence or increased cross s reactivity with anti-AGE antibodies. The increase in fluorescence seems to precede formation of AGE specific antigenic epitopes. This increase in fluorescence is used to monitor the increased AGE formation in vitro (Brownlee M et al, Science 1986; 232:1629-1632). In addition to the increase in the fluorescence, one of the most important features of in vitro AGE formation is the to formation of antigenic epitopes that are specific to AGE and not to the native proteins. Therefore, it is possible to raise antibodies against advanced glycation end products of one protein and use them to detect AGE formation in other proteins. This has served as an important analytical tool in AGE research.
Due to the clinical significance of AGE formation, many approaches are is being used to diagnose, prevent, or revert AGE formation in the body. The formation of AGE could be inhibited by reacting with an early glycosylation product that results from the original reaction between the target protein and glucose. The inhibition was believed to take place as the reaction between the inhibitor and the early glycosylation product appeared to interrupt the subsequent ao reaction of the glycosylated protein with additional protein material to form the cross linked late stage product. Compounds Iike aminoguanidine act to inhibit AGE formation by such mechanism.
The formation of AGE on long-lived proteins is also associated with cross-linking of these proteins. The AGE derived protein cross-links have been shown s to be cleaved by compounds like N- phenacyl thiazolium bromide (PTB), which reacts with and cleaves covalent, AGE derived protein cross links (Vasan et al.
Nature 1996; 382: 275-278; US 5,853,703, Date of Patent : Dec. 29, 1998). The mechanism of reducing the AGE content in tissues is expected to take place relatively rapidly, in contrast to aminoguanidine, which acts slowly by its very la nature of mechanism of action. This current specification is related to compounds of pyridinium class, which break pre-formed AGE, like PTB, and in some cases even more effectively than PTB.
SUMMARY OF THE INVENTION
is The main objective of the present invention is to provide a class of compounds of the pyridinium series which are useful for the management of diabetes and aging-related vascular complications, and particularly in the treatment of complications of diabetes mellitus and other aging-related conditions including kidney disease, nerve damage, atherosclerosis, retinopathy anal ao dermatological conditions. The invention also extends the method to reverse the discoloration of teeth resulting from nonenzymatic browning in the oral cavity which comprises administration of an amount effective to reverse the pre-formed advanced glycosylation crosslinks etc.
Another object of the present invention is to provide compounds of the Zs pyridinium series, which exhibit AGE breaking activities.
s to FIELD OF THE INVENTION
The present invention relates to a class of compounds of pyridinium series and to their use in treatment of diabetes and related illnesses. More particularly is the invention relates to compounds of this series, methods for their preparation, pharmaceutical composition containing these compounds and their use in the treatment of complications of diabetes mellitus. The compounds of this series exhibit AGE breaking activity, which is essential for the treatment of diabetic and aging-related complications including kidney disease, nerve damage, 2o atherosclerosis, retinopathy and dermatological conditions. The invention also extends to the method of reversing the discoloration of teeth resulting from nonenzymatic browning in the oral cavity which comprises administration of an amount effective to reverse pre-formed advanced glycosylation crosslinks.
BACKGROUND OF THE INVENTION
2s Maillard in 1912 found that reducing sugars, such as glucose and ribose react with proteins to form brown pigments. Further studies have shown that this is an irreversible non-enzymatic reaction, which occurs irl several natural systems including stored foodstuff. Maillard reaction occurs in two stages, early and s advanced. Initially, proteins react with glucose to form stable Amadori products, which subsequently cross-links to form advanced glycation end products (AGE).
In most cases, the formation of AGE also accompanies browning of the proteins and increase in the fluorescence.
In diabetes, where blood glucose level is significantly higher than normal, to the reaction of glucose with several proteins such as haemoglobin, lens crystallin and collagen, gives rise to the formation of AGE, which in turn, is responsible for the complications associated with diabetes, such as nephropathy, microangiopathy, endothelial dysfunction and other organ dysfunctions. In addition, the activity of several growth factors, such as basic fibroblast growth is factor, is also impaired. AGE products, unlike normal proteins in tissue, have a slower rate of turnover and replenishment. It has been reported that AGE
products may in fact elicit a complex immunological reaction involving RAGE
(Receptor for Advanced Glycation End Products) receptors and activation of several incompletely defined immunological processes. It has been documented 2o that diabetes with evidence of microangiopathy and macroangiopathy also show evidence of oxidative stress, the mechanism of which has not been elucidated.
in vitro AGE formation can be studied in the laboratory by incubating reducing sugars, such as ribose or glucose with bovine serum albumin. AGE
formation can be detected by increase in the fluorescence or increased cross s reactivity with anti-AGE antibodies. The increase in fluorescence seems to precede formation of AGE specific antigenic epitopes. This increase in fluorescence is used to monitor the increased AGE formation in vitro (Brownlee M et al, Science 1986; 232:1629-1632). In addition to the increase in the fluorescence, one of the most important features of in vitro AGE formation is the to formation of antigenic epitopes that are specific to AGE and not to the native proteins. Therefore, it is possible to raise antibodies against advanced glycation end products of one protein and use them to detect AGE formation in other proteins. This has served as an important analytical tool in AGE research.
Due to the clinical significance of AGE formation, many approaches are is being used to diagnose, prevent, or revert AGE formation in the body. The formation of AGE could be inhibited by reacting with an early glycosylation product that results from the original reaction between the target protein and glucose. The inhibition was believed to take place as the reaction between the inhibitor and the early glycosylation product appeared to interrupt the subsequent ao reaction of the glycosylated protein with additional protein material to form the cross linked late stage product. Compounds Iike aminoguanidine act to inhibit AGE formation by such mechanism.
The formation of AGE on long-lived proteins is also associated with cross-linking of these proteins. The AGE derived protein cross-links have been shown s to be cleaved by compounds like N- phenacyl thiazolium bromide (PTB), which reacts with and cleaves covalent, AGE derived protein cross links (Vasan et al.
Nature 1996; 382: 275-278; US 5,853,703, Date of Patent : Dec. 29, 1998). The mechanism of reducing the AGE content in tissues is expected to take place relatively rapidly, in contrast to aminoguanidine, which acts slowly by its very la nature of mechanism of action. This current specification is related to compounds of pyridinium class, which break pre-formed AGE, like PTB, and in some cases even more effectively than PTB.
SUMMARY OF THE INVENTION
is The main objective of the present invention is to provide a class of compounds of the pyridinium series which are useful for the management of diabetes and aging-related vascular complications, and particularly in the treatment of complications of diabetes mellitus and other aging-related conditions including kidney disease, nerve damage, atherosclerosis, retinopathy anal ao dermatological conditions. The invention also extends the method to reverse the discoloration of teeth resulting from nonenzymatic browning in the oral cavity which comprises administration of an amount effective to reverse the pre-formed advanced glycosylation crosslinks etc.
Another object of the present invention is to provide compounds of the Zs pyridinium series, which exhibit AGE breaking activities.
s Yet another object of the present invention is to provide a method of preparation of compounds of the pyridinium series which exhibit AGE breaking activities.
Still another object of the invention is to provide pharmaceutical to compositions with a new class of compounds of the pyridinium series according to the invention and their pharmaceutically acceptable salts in combination with suitable carriers, solvents, excepients, diluents and other media normally employed in preparing such compositions.
Still another object of the invention is to provide a method of treatment of a is diabetic patient by administration of the compounds of the invention, either singly or in combination with drugs for anti-diabetic therapy, or pharmaceutically acceptable salts thereof in required dosage in admixture with pharmaceutically acceptable diluent, solvent, excepients, carriers or other media as may be appropriate for the purpose.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides for a new class of AGE breakers, of general 2s formula I, s a O
(I) wherein is Rl is -Y-R3 Y is selected from oxygen or NH.
.R3 is selected from hydrogen, alkyl, aryl RZ is selected from group consisting of alkyl, -Oalkyl, aryl, -Oaryl, NHalkyl and -NHaryl 2o X is selected from group consisting of a halide ion, acetate ion, perchlorate ion, sulfonate ion, oxalate ion, citrate ion, tosylate ion, maleate ion, mesylate ion, carbonate ion, sulfite ion, phosphoric hydrogen ion, phosphonate ion, phosphate ion, BF4 , PF6 , etc.
with proviso that, 2s (a) when Rl is phenyl, then R2 is also phenyl, and (b) when R2 is phenyl and X is halide ion, then Rl is other than -OCH3.
As used herein "alkyl" refers to an optionally substituted, saturated hydrocarbon group joined by single carbon-carbon bonds and having 1-4 carbon s atoms joined together. The saturated alkyl hydrocarbon group may be linear or branched. The substituent is -OH.
As used herein "aryl" refers to an optionally substituted aromatic group with atleast one ring having a conjugated pi- electron system, containing upto two conjugated or fused ring systems. Aryl includes carbocyclic aryl and heterocyclic to aryl all of which may be optionally substituted with halogen, sulfonamido, thio, amino, cyano, -Oalkyl, -NHalkyl, hydroxy, folmyl, -Oaryl and -NHaryl.
The representative compounds of general formula I which are novel are listed in Table IA. These compounds with the following chemical names are suggested by way of example alone and in no way restrict the invention.
is 3-Carbonylamino-1-(2-(2,4-dichlorophenyl)-2-oxoethyl)) pyridinium bromide (compound 1 ).
3-(Tetrahydrobenzothiazol-2-yl)aminocarbonyl-1-(2-(2,4-dichlorophenyl)-2-oxoethyl)pyridinium bromide (compound 2 ).
1-(2-Phenyl-2-oxoethyl)-3-((2-hydroxyethyl)aminocarbonyl) pyridinium bromide 20 (compound 3).
3-Carbonylamino-1-(2-thien-2'-yl-2-oxoethyl~yridinium bromide(compound 4 ).
1-(2-Phenyl-2-oxoethyl)-3-((p-sulfonamidophenylene)aminocarbonyl) pyridinium bromide (compound 5 ).
Still another object of the invention is to provide pharmaceutical to compositions with a new class of compounds of the pyridinium series according to the invention and their pharmaceutically acceptable salts in combination with suitable carriers, solvents, excepients, diluents and other media normally employed in preparing such compositions.
Still another object of the invention is to provide a method of treatment of a is diabetic patient by administration of the compounds of the invention, either singly or in combination with drugs for anti-diabetic therapy, or pharmaceutically acceptable salts thereof in required dosage in admixture with pharmaceutically acceptable diluent, solvent, excepients, carriers or other media as may be appropriate for the purpose.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides for a new class of AGE breakers, of general 2s formula I, s a O
(I) wherein is Rl is -Y-R3 Y is selected from oxygen or NH.
.R3 is selected from hydrogen, alkyl, aryl RZ is selected from group consisting of alkyl, -Oalkyl, aryl, -Oaryl, NHalkyl and -NHaryl 2o X is selected from group consisting of a halide ion, acetate ion, perchlorate ion, sulfonate ion, oxalate ion, citrate ion, tosylate ion, maleate ion, mesylate ion, carbonate ion, sulfite ion, phosphoric hydrogen ion, phosphonate ion, phosphate ion, BF4 , PF6 , etc.
with proviso that, 2s (a) when Rl is phenyl, then R2 is also phenyl, and (b) when R2 is phenyl and X is halide ion, then Rl is other than -OCH3.
As used herein "alkyl" refers to an optionally substituted, saturated hydrocarbon group joined by single carbon-carbon bonds and having 1-4 carbon s atoms joined together. The saturated alkyl hydrocarbon group may be linear or branched. The substituent is -OH.
As used herein "aryl" refers to an optionally substituted aromatic group with atleast one ring having a conjugated pi- electron system, containing upto two conjugated or fused ring systems. Aryl includes carbocyclic aryl and heterocyclic to aryl all of which may be optionally substituted with halogen, sulfonamido, thio, amino, cyano, -Oalkyl, -NHalkyl, hydroxy, folmyl, -Oaryl and -NHaryl.
The representative compounds of general formula I which are novel are listed in Table IA. These compounds with the following chemical names are suggested by way of example alone and in no way restrict the invention.
is 3-Carbonylamino-1-(2-(2,4-dichlorophenyl)-2-oxoethyl)) pyridinium bromide (compound 1 ).
3-(Tetrahydrobenzothiazol-2-yl)aminocarbonyl-1-(2-(2,4-dichlorophenyl)-2-oxoethyl)pyridinium bromide (compound 2 ).
1-(2-Phenyl-2-oxoethyl)-3-((2-hydroxyethyl)aminocarbonyl) pyridinium bromide 20 (compound 3).
3-Carbonylamino-1-(2-thien-2'-yl-2-oxoethyl~yridinium bromide(compound 4 ).
1-(2-Phenyl-2-oxoethyl)-3-((p-sulfonamidophenylene)aminocarbonyl) pyridinium bromide (compound 5 ).
s 1-(2-Ethoxy-2-oxoethyl)-3-((2-hydroxyethyl)aminocarbonyl)pyridinium bromide.
(compound 6 ).
1-(2-Phenyl -2- oxoethyl) -3-(isopropyloxycarbonyl) pyridinium bromide (compound 7).
1-(2-Methyl-2-oxoethyl~3-((2-hydroxyethyl)aminocarbonyl) pyridinium chloride to (compound 8).
1-(2-Thien-2'-yl-2-oxoethyl}-3-((2-hydroxyethyl)aminocarbonyl)pyridinium bromide (compound 9 ).
1-(2-(2,4 - Dichlorophenyl-2-oxoethyl) -3- (isopropyloxycarbonyl) pyridinium bromide (compound 10 ).
is 1- (2-Phenyl - 2- oxoethyl) - 3- ((4-methylthiazol - 2 -yl) aminocarbonyl) pyridinium bromide (compound 11 ).
1-(2-Phenylamino-2-oxoethyl)-3-(n-butyloxycarbonyl)pyridinium chloride (compound 12 ).
I -(2- Phenylamino - 2- oxoethyl ) - 3 - (n-butylaminocarbonyl ) pyridinium chloride (compound 13 ).
1- (2- Phenylamino - 2- oxoethyl )- 3- ((2-hydroxyethyl)aminocarbonyl) pyridinium chloride (compound 14 ).
(compound 6 ).
1-(2-Phenyl -2- oxoethyl) -3-(isopropyloxycarbonyl) pyridinium bromide (compound 7).
1-(2-Methyl-2-oxoethyl~3-((2-hydroxyethyl)aminocarbonyl) pyridinium chloride to (compound 8).
1-(2-Thien-2'-yl-2-oxoethyl}-3-((2-hydroxyethyl)aminocarbonyl)pyridinium bromide (compound 9 ).
1-(2-(2,4 - Dichlorophenyl-2-oxoethyl) -3- (isopropyloxycarbonyl) pyridinium bromide (compound 10 ).
is 1- (2-Phenyl - 2- oxoethyl) - 3- ((4-methylthiazol - 2 -yl) aminocarbonyl) pyridinium bromide (compound 11 ).
1-(2-Phenylamino-2-oxoethyl)-3-(n-butyloxycarbonyl)pyridinium chloride (compound 12 ).
I -(2- Phenylamino - 2- oxoethyl ) - 3 - (n-butylaminocarbonyl ) pyridinium chloride (compound 13 ).
1- (2- Phenylamino - 2- oxoethyl )- 3- ((2-hydroxyethyl)aminocarbonyl) pyridinium chloride (compound 14 ).
s 1- (2- (2,4 - Dichlorophenyl ) - 2-oxoethyl) - 3- (n - butoxycarbonyl) pyridinium bromide (compound 15 ) 1-(2 - (2, 4 - Dichlorophenyl) - 2-oxoethyl) - 3- (n-butylamino-carbonyl ) pyridinium bromide (compound 16 ).
Further, some known pyridine derivatives have also been studied for their AGE
to breaking activity, which was not known earlier for these molecules, and are as listed in Table IB, with their chemical names as given below:
1- (2-Phenyl-2-oxoethyl) -3- (1-phenyl-1-oxomethyl) pyridinium bromide (compound 17 : (Ref-. Chemical Abstracts: 91, P47378Y, (1979)) 1- (2 Phenyl - 2-oxoethyl ) - 3- (methoxycarbonyl ) pyridinium bromide is (compound 18 : (Ref Chemical Abstracts: 91, P47378Y, (1979)) TahlP 1A - Pvridinium derivatives (Novell Compound -Rl - 2 -X
No.
1 NH2 2,4-dichloro Br hen 1 2 tetrahydrobenzo-thiazol-2-yl-2,4-dichlorophenylBr amino 3 NHCH2CH20H Phen 1 Br 4 NHz 2 thien 1 Br -sulfonamido- hen lease Phen 1 Br amino 6 NHCHZCHZOH OEt Br 7 OCH CH3 2 Phen 1 Br g NHCH2CH20H CH3 Cl 9 NHCH2CH20H 2-thiea 1 Br OCH CH3 2 2,4-dichloro Br hen 1 11 4-meth lthiazol-2- 1 aminoPhen 1 Br 12 OCH2CH2CH2CH3 NHPh Cl 13 NHCH2CH2CH2CH3 NHPh Cl 14 N_HCH2CH20H NHPh Cl 15 OCH2CH2CH2CH3 2,4-dichloro hen Br 16 NHCH2CH2CH2CH3 2,4-dichloro hen Br s Table IB - Pyridinium Derivatives (Known) Compound -Rl -R2 -X
No.
17 Phen 1 Phen 1 Br 18 OCH3 Phen 1 Br to According to one embodiment of the present invention, the present compounds are used for the treatment of diabetic complications, aging-related complications including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological conditions and colouration of teeth occurring due to the higher levels of preformed AGE. The increased levels of preformed AGE can is be brought under control by breaking the AGE products using compounds mentioned in the invention.
The invention also provides a process for the preparation of compounds of the pyridinium series.
The said process for the preparation of compound 1, comprises, adding a 2o solution of 2,4- dichlorophenacyl bromide in toluene to nicotinamide dissolved in refluxing toluene, refluxing for seven and half hours, cooling, filtering the precipitated solid, dissolving in methanol, treating with activated charcoal, s concentrating under vacuum, cooling in ice-salt mixture, filtering the precipitated solid and washing with methanol to obtain the desired compound.
Siml~arly, the other compounds of general formula I, are prepared from properly substituted pyridine derivatives followed by quarternization with appropriate reagent by refluxing in alcoholic solvents like methanol, ethanol, to propanol, etc., and high boiling solvents like, toluene or xylene for 6 -48 hrs. to give the desired compounds.
The in vitro AGE formation, studied in the laboratory, by incubating reducing sugar n'bose, with protein bovine serum albumin, resulted in browning of solution and increase in the fluorescence. Fluorescence was used as the criteria to is monitor the increased AGE formation.
Example 1 AGE breaker activity has been confirmed by the screenine_prrocedure as mentioned below:
Materials:
Zo Bovine serum albumin (fraction V) (BSA) Ribose, analytical grade Phosphate buffered saline (PBS) Equipment:
Microplate ELISA Reader - Spectramax Plus (Molecular Devices, USA) s Microplate washer, (Bio -Tec Instruments, USA) pH meter Methods of experiment:
160 mg/ml of protein, bovine serum albumin, BSA and 1.6M glucose sugar were dissolved in phosphate buffered saline, PBS. Sodium azide was added at l0 0.02% concentration as a preservative. The solution was filtered asceptically through a 0.22 E,iM filter and kept for aging at 37°C for 16 weeks.
After 16 weeks the solution was dialyzed against PBS, aliquoted and stored at -20°C.
To determine the AGE breaking activity, lOp,g/ml and 100~.g/ml of the 16 weeks AGE-BSA was incubated with different concentrations of the test is compounds at 37°C for 24 hours and AGE breaking activity of the test compounds by ELISA was determined.
ELISA was performed as follows:
1. Different concentrations of 16 weeks AGE-BSA were coated on a microtitre plate as standard. Each concentration is coated in triplicates.
20 2. The test samples were coated on microtitre plate at a concentration of 5 ng. to 20 ng per well in triplicates.
3. The plate was incubated at 37°C for one hour.
4. After incubation the plate was washed with PBST (PBS with 0.05% Tween 20).
s 5. Blocking with S% slummed milk in PBS at 37°C for one hour was done.
6. The plate was washed with PBST.
7. Primary antibody against AGE-BSA was added and the plate is incubated at 37°C for one hour.
8. The plate was washed with PBST
l0 9. Secondary antibody anti rabbit HRPO (Horse-Radish Per Oxidase) conjugate was added and the plate is incubated at 37°C for one hour.
Further, some known pyridine derivatives have also been studied for their AGE
to breaking activity, which was not known earlier for these molecules, and are as listed in Table IB, with their chemical names as given below:
1- (2-Phenyl-2-oxoethyl) -3- (1-phenyl-1-oxomethyl) pyridinium bromide (compound 17 : (Ref-. Chemical Abstracts: 91, P47378Y, (1979)) 1- (2 Phenyl - 2-oxoethyl ) - 3- (methoxycarbonyl ) pyridinium bromide is (compound 18 : (Ref Chemical Abstracts: 91, P47378Y, (1979)) TahlP 1A - Pvridinium derivatives (Novell Compound -Rl - 2 -X
No.
1 NH2 2,4-dichloro Br hen 1 2 tetrahydrobenzo-thiazol-2-yl-2,4-dichlorophenylBr amino 3 NHCH2CH20H Phen 1 Br 4 NHz 2 thien 1 Br -sulfonamido- hen lease Phen 1 Br amino 6 NHCHZCHZOH OEt Br 7 OCH CH3 2 Phen 1 Br g NHCH2CH20H CH3 Cl 9 NHCH2CH20H 2-thiea 1 Br OCH CH3 2 2,4-dichloro Br hen 1 11 4-meth lthiazol-2- 1 aminoPhen 1 Br 12 OCH2CH2CH2CH3 NHPh Cl 13 NHCH2CH2CH2CH3 NHPh Cl 14 N_HCH2CH20H NHPh Cl 15 OCH2CH2CH2CH3 2,4-dichloro hen Br 16 NHCH2CH2CH2CH3 2,4-dichloro hen Br s Table IB - Pyridinium Derivatives (Known) Compound -Rl -R2 -X
No.
17 Phen 1 Phen 1 Br 18 OCH3 Phen 1 Br to According to one embodiment of the present invention, the present compounds are used for the treatment of diabetic complications, aging-related complications including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological conditions and colouration of teeth occurring due to the higher levels of preformed AGE. The increased levels of preformed AGE can is be brought under control by breaking the AGE products using compounds mentioned in the invention.
The invention also provides a process for the preparation of compounds of the pyridinium series.
The said process for the preparation of compound 1, comprises, adding a 2o solution of 2,4- dichlorophenacyl bromide in toluene to nicotinamide dissolved in refluxing toluene, refluxing for seven and half hours, cooling, filtering the precipitated solid, dissolving in methanol, treating with activated charcoal, s concentrating under vacuum, cooling in ice-salt mixture, filtering the precipitated solid and washing with methanol to obtain the desired compound.
Siml~arly, the other compounds of general formula I, are prepared from properly substituted pyridine derivatives followed by quarternization with appropriate reagent by refluxing in alcoholic solvents like methanol, ethanol, to propanol, etc., and high boiling solvents like, toluene or xylene for 6 -48 hrs. to give the desired compounds.
The in vitro AGE formation, studied in the laboratory, by incubating reducing sugar n'bose, with protein bovine serum albumin, resulted in browning of solution and increase in the fluorescence. Fluorescence was used as the criteria to is monitor the increased AGE formation.
Example 1 AGE breaker activity has been confirmed by the screenine_prrocedure as mentioned below:
Materials:
Zo Bovine serum albumin (fraction V) (BSA) Ribose, analytical grade Phosphate buffered saline (PBS) Equipment:
Microplate ELISA Reader - Spectramax Plus (Molecular Devices, USA) s Microplate washer, (Bio -Tec Instruments, USA) pH meter Methods of experiment:
160 mg/ml of protein, bovine serum albumin, BSA and 1.6M glucose sugar were dissolved in phosphate buffered saline, PBS. Sodium azide was added at l0 0.02% concentration as a preservative. The solution was filtered asceptically through a 0.22 E,iM filter and kept for aging at 37°C for 16 weeks.
After 16 weeks the solution was dialyzed against PBS, aliquoted and stored at -20°C.
To determine the AGE breaking activity, lOp,g/ml and 100~.g/ml of the 16 weeks AGE-BSA was incubated with different concentrations of the test is compounds at 37°C for 24 hours and AGE breaking activity of the test compounds by ELISA was determined.
ELISA was performed as follows:
1. Different concentrations of 16 weeks AGE-BSA were coated on a microtitre plate as standard. Each concentration is coated in triplicates.
20 2. The test samples were coated on microtitre plate at a concentration of 5 ng. to 20 ng per well in triplicates.
3. The plate was incubated at 37°C for one hour.
4. After incubation the plate was washed with PBST (PBS with 0.05% Tween 20).
s 5. Blocking with S% slummed milk in PBS at 37°C for one hour was done.
6. The plate was washed with PBST.
7. Primary antibody against AGE-BSA was added and the plate is incubated at 37°C for one hour.
8. The plate was washed with PBST
l0 9. Secondary antibody anti rabbit HRPO (Horse-Radish Per Oxidase) conjugate was added and the plate is incubated at 37°C for one hour.
10. The plate was washed with PBST.
11. Colour development with OPD (orthophenylenediamine dihydrochloride) and hydrogen peroxide was done.
is 12. OD (optical density) at (450nm reading - 620nm reading) was measured after incubation at 37°C for 15 minutes with Microplate ELISA Reader.
The breaker activity of the compounds were detenmined by the following formula:
Breaker activity = OD4~ZOControl - OD45o.62oTest Zo _~_~~~_~_____~~______ _ x 100 OD 450.20 Control OD4so.~zoControl=Absorbance of 20ng AGE-BSA after incubation at 37°C
for 24 hours without test compound i3 s OD4so.~2oTest=Absorbance of 20ng AGE-BSA after incubation at 37°C for hours with required concentration of test compound Using specific examples, the % AGE breaking activity was calculated and recorded in Table 2.
Table 2 Sample Concentration %Breakage PTB 10 mM 27 20 mM 47 Compound 3 10 mM 5 Compound 4 10 mM 3 Compound 6 10 mM 43 Compound 9 T 10 mM 50 Compound 12 10 mM 57 Compound 13 10 mM 27 Compound 14 20 mM 48 Compound 17 5 mM 45 Compound 18 20 mM 36 to s Hence, for example, compound 12 has significant AGE - breaking activity i.e.
a comparatively much superior potency vis - a - vis PTB.
The following examples give method for preparation of the specific compounds of the invention as given in Table 1. The following compounds suggested are by way of example alone and in no way restrict the invention.
to Example 2 Preparation of 3- carbonvlamino -1- (2- (2,4-dichlorouhenyl) -Z- oxoethvl) pyridinium bromide (comuound 1) Nicotinamide (1.228, O.Oi mol) was dissolved in refluxing toluene (40 ml) and a solution of 2,4-dichlorophenacyl bromide (3.Og, 0.012moI) in 14m1 of is toluene was added. The reaction mixtwre was refluxed for 7.5 hours and cooled.
The precipitated solid was filtered and dissolved in methanol, decolourized with activated charcoal and concentrated under vacuum to one-fourth volume. It was cooled in ice - salt mixture and the precipitated solid was filtered and washed with methanol (3x10m1) to afford a pure solid.
2o Yield : 39%
m.p. : 237-239°C
IR(KBr,clri 1) : 3331, 3133, 1706, i6?8 1H NMR (DMS4d6, 400 MHz) 8 : 9.54(lH,s), 9.18-9.11(ZH,m), 8.67(lH,s), 8.40(lH,t), 8.42-8.38(2H,m), 7.88(lH,s), 7.75 -7.72(lH,m), 6.49(2H,s) s Mass (m/z): 309,310,311,312,187,159 According to the above mentioned procedure the following compounds are synthesized by reacting the corresponding pyridine derivatives with appropriate reagents by refluxing in alcoholic solvents like methanol, ethanol, propanol, etc.
and high boiling solvents like toluene or xylene for 6-48 hours to give the desired to compounds:
Eaamule 3 3-(Tetrahvdrobenzothiazol-2-vl)aminocarbonylY 1-(2-(2,4-dichloropheny,~,l~2-ogoethyl) uyridinium bromide (comuound 2):
Yield : 48%
is m.p. : 165 -167 °C(decomp.) IR(KBr,cni 1) : 3333, 1714, 1684, 1635 1H NMR(CD30D, 400MHz) 8: 9.45(IH,s), 9.27-9.24(lH,m), 8.92-8.91(1H, m), 8.24 - 8.21(1H, m), 8.01 - 7.99(1H, m), 7.72 - 7.71(1H, m) 7.57-7.54(lH,m), 2.59-2.57 (4H,m), 1.85(4H,m) ao Mass (m/z) : 446, 447, 448, 449, 416, 307 and 266 Ezamule 4 1-(2- Phenyl -2- ozoethyl) -3- ((2- hydrogyethyl) aminocarbonvl) pyridinium bromide (comuound 3):
Yield : 98%
s m.p. : 182 - 184°C(decomp.) IR(KBr,clii 1) : 3289, 3241, 1690 and 1660 1H NMR(DMSOd6, 400MHz) 8: 9.47(lH,s), 9.21(lH,t), 9.09(2H,t), 8.41-8.37(lH,m), 8.08-8.04(2H,m), 7.82-7.78(lH,m), 7.69-7.65(2H,m), 6.52(2H,s), 4.86(lH,t), 3.58-3.54(2H,m), 3.42-3.38(2H,m) to Mass (m/z) : 285,242,149,1 I 9,91 Example 5 3-Carbonylamino-1- (2-thien-2'-yl-2-oxoethvl) nyridinium bromide compound 4 ).
Yield : 35%
is m.p. : 212 - 215°C (decomp.) IR(KBr,cni 1) : 3295, 3126, 1680, 1671, 1640 1H NMR (DMSOd6, 400 MHz) 8: 9.49(IH,s), 9.13-9.11(lH,d), 9.07-9.05(lH,d), 8.60(lH,bs), 8.40-8.38(lH,m), 8.25-8.19(3H,m),7.43-7.40,(lH,t), 6.44(2H,s) Mass(m/z) : 247,248,249,193 2o Examine 6 1- (2-Phenyl -2- oxoethyl) -3- ((u-sulfonamidophenylene) aminocarbonYl) pyridinium bromide (comuound 5):
Yield : 44%
m.p. : 188-190°C
s IR(KBr,ctri') : 3296, 1700, 1679.
1H NMR (DMSOd~, 400MHz) S: 11.25 (lH,s), 9.58 (lH,s), 925 (lH,d), 9.16 (1H, d), 8.45 (lH,t), 8.10 (2H,d), 7.94 (2H,d), 7.86 (2H,d), 7.82(lH,t), 7.68(2H,t), 7.36(2H,s), 6.5(2H,s) Mass (m/z) : 396, 277 to Example 7 1- (2- Ethoay -2- oxoethyl) -3- ((2- hydroayethvhocarbonyl) uvrid, i~n~'um bromide compound 6):
Yield : 87%
m.p. : 138-140°C
is IR(KBr, cni ~) : 1748,1669 ~H NMR {CD30D, 400 MHz) 8: 9.43 (lH,s), 9.09-9.02 (2H,ln), 8.26 (lH,m), 5.64 (2H,s), 4.31 (2H,~, 3.73 (2H,t), 3.54 {2H,t}, 1.32 (3H,t) Mass (m/z) : 251, 252, 165, 166 Example 8 Zo 1- (2- Phenyl -2- oxoethvl) -3- (isoprouyloxycarbonvl) uvridinium bromide (compound 7):
Yield : 46%
m.p. : 172-174°C
IR(KBr, cm 1) : 1726, 1692 s 'H NMR (DMSOd6, 400MHz) 8: 9.55 (lH,s), 9.16 (lH,d), 9.08(lH,d), 8.39-8.36 (lH,m), 8.04 (2H,d), 7.77 (lH,t), 7.64 (2H,t), 6.53 (2H,s), 5.25-5.19 (lH,m), 1.34 (6H,d) Mass (m/z) : 284, 285, 242 Example 9 l0 1- (2- Methyl-2-oxoethyl) -3- ((2- hydroxyethvl) aminocarbonvl) pyridinium chloride (compound 8):
Yield : 47%
m.p. : 178-180°C
IR(KBr, clri') : 1727, 1660 is 1H NMR (DMSOdb, 400 MHz) S: 9.33 (lH,t), 9.30 (iH,s), 9.06(lH,d), 8.90 (lH,d), 8.25-8.21 (lH,m), 5.75 (2H,s), 4.84(lH,bs), 3.47 (2H,t), 3.30 (2H,t), 2.23 (3H,s) Mass (m/z) : 223, 224, 225 Example 10 20 1- (2- Thien -2'-yl -2- oxoethyl) -3- ((2- hvdroxyethvly aminocarbonyl~
pyridinium bromide (compound 9):
Yield : 60%
m.p. : 207-209°C
IR(KBr, czri ~) : 1673, 1656 s 1H NMR (DMSOd6, 400MHz} 8: 9.47 (lH,s}, 9.18-9.05 (3H,m),8.38-8.34 (lH,m), 8.23-8.19 (2H,m), 7.39 (lH,t), 6.44 (2H,s),3.55-3.50 (2H,m), 3.40-3.37 (2H,m) Mass (m/z) : 291, 292, 293 Eaample 11 l0 1- (2- (2,4- Dichloronhenyly -2- ozoethyl) -3- (isouropyloaycarbonvl) ~yridinium bromide (comuound 101:
Yield : 26%
m.p. : 160-162°C
is IR (KBr, cm 1) : 1726, 1705 1H NMR (DMSOdb, 400 MHz) 8: 9.55 (lH,s}, 9.15 (lH,d), 9.08(lH,d), 8.40-8.36 (lH,m), 8.11 (lH,d), 7.89 (lH,bs), 7.75-7.72 (lH,m), 6.44 (2H,s), 5.26-5.20 (lH,m), 1.34 (6H,d).
Mass (m/z) : 352, 353, 354, 310 2o Eaamule 12 1- (2- Phenyl -2- oaoethyl) -3- ((4- methylthiazol -2- yl) aminocarb pvridinium bromide (compound 11):
Yield : 30%
m.p. : 165-167°C
s IR (KBr, clri I) : 3409, 3319 and 1698 1H NMR (DMSOd6, 400 MHz) 8: 9.58 (lH,s), 9.22 (lH,d), 9.11(lH,d), 8.42-8.38 (lH,m), 8.07 (2H,d), 7.81 (lH,t), 7.68(2H,t), 6.86 (lH,bs), 6.56 (2H,s), 2.30 (3H,s) Mass (m/z) : 337, 338, 232, 105.
to Example 13 1- (2- Phenylamino -2- oxoethyl) -3- (n- butoxycarbonvl) pyridinium chloride (compound 1 Yield : 10%
m.p. : 150-152°C
is IR (KBr, crri') : 3228, 1742, 1678 (bs) 'H NMR (DMSOd6, 400 MHz) 8: 10.96 (lH,s), 9.65 (lH,s), 9.28(lH,t), 9.09 (lH,d), 8.37 - 8.34 (lH,m), 7.b2 - 7.59 (2H,m),7.37 - 7.33 (2H,m), 7.11 (lH,t), 5.79 (2H,s), 4.41(2H,t), 1.76-1.72(2H,m), 1.48-1.43 (2H,m), 0.94 (3H,t) Mass (m/z) : 314, 3I5 2o Example 14 1- (2- Phenylamino -2- ozoethyl) -3- (n- butvlaminocarbonyl) pyridinium chloride (compound 13):
Yield : 37%
m.p. : 182-185°C
s IR (KBr, clri 1) : 3245, 1742, 1679 'H NMR (DMSOd~, 400MHz) 8: 10.97 (lH,s), 9.50(IH,s), 9.24(lH,t), 9.13 (lH,d), 9.02 (lH,d), 8.28-8.25 (lH,m), 7.57 (2H,d), 7.30(2H,t), 7.05 (lH,t), 5.70 (2H,s), 3.30 - 3.26 (2H,m), 1.52 -1.48 (2H,m), 1.34 -1.30 (2H,m), 0.86 (3H,t) Mass (m/z) : 312, 313 to Example 15 1- (2- Phenylamino -2- oxoethyl) -3- ((2- hvdroavethyl) aminocarbonyl pvridinium chloride (comuound l14 Yield : 58%
m.p. : 225-227°C
is IR (KBr, clri 1) : 3448, 3271, 1702 and 1663 1H NMR (DMSOd6,400 MHz) 8: 11.07 (lH,s), 9.58 (lH,s) 9.35(lH,t), 9.I7 (lH,d), 9.11 (lH,d), 8.33-8.29 (lH,m), 7.60(2H,d), 7.32 (2H,t), 7.08 (lH,t), 5.75 (2H,sj, 4.90 (lH,t), 3.57-3.53 (2H,m), 3.40-3.36 (2H,m) Mass (m!z) : 300, 301, 302 zo Exam lu a 16 1- (2- (2,4- Dichlorophenyl) -2- oxoethvl) -3- (n- butoxycarbonyl) pvridinium bromide (com~round 15):
Yield : 38%
m.p. : 154-156°C
s IR(KBr, clri 1) : 3435, 3389, 1731 and 1704 1H IVMR (DMSOd6, 400 MHz) 8: 9.60 (lH,s), 9.21 (lH,d), 9.14(lH,d), 8.43 (lH,t), 8.16 (lH,d), 7.92 (lH,s), 7.78-7.76(lH,m), 6.51 (2H,s), 4.42 (2H,t), 1.76-1.72 (2H,m), 1.48-1.42 (2H,m), 0.94 (3H,t) Mass (m/z) : 366, 367, 368, 369, 370 to Example 17 1- (2- (2,4- Dichlorophenyl) -2- oxoethyl) -3- (n-butylaminocarbonyl) pyridinium bromide (compound 16):
Yield : 35%
m.p. : 142-144°C
is IR(KBr, clri') : 3382, 1698, 1672 1H NMR (DMSOd6, 400 MHz) 8: 9.37 (lH,s), 9.07 (lH,t), 8.99(2H,t), 8.31-8.28 (lH,m), 8.04 (lH,d) 7.82-7.81 (lH,d), 7.68-7.65 (lH,m), 6.34(2H,s), 3.27-3.24 (2H,m), 1.47-1.43 (2H,m),1.29-1.24 (2H,m), 0.81 (3H,t) Mass (m/z) : 365, 366, 367, 368, 369 2o Pharmaceutical Compositions Pharmaceutical compositions may be prepared with a pharmaceutically effective quantity of compounds of general formula I, individually or in combination. The following pharmaceutical formulations suggested are by way of example alone and in no way restrict the forms in which they can be used.
s Oral formulations Oral formulations may be administered as solid dosage forms for example pellets, powders, sachets or discreet units such as tablets or capsules and like.
Other orally administered pharmaceutical preparations include monophasic and biphasic liquid dosage forms either in ready to use form or forms suitable for to reconstitution such as mixtures, syrups, suspensions or emulsions. The preparations in addition may contain diluents, dispersing agents, buffers, stabilizers, solubilizers, surfactants, preservatives, chelating agents and/
or other pharmaceutical additives as are used. Aqueous or non-aqueous vehicle or their combination may be used and if desired may contain suitable sweetener, flavoring Is agent or similar substances. In case of suspension or emulsion a suitable thickening agent or suspending agent or emulsifying agent may be present in addition. Alternatively, the compounds may be administered as such in their pure form unassociated with other additives for example as capsules or sachets. It may also be administered with a vehicle. Pharmaceutical preparations can have a slow, 2o delayed or controlled release of active ingredients as is provided by a matrix or diffusion controlled system.
When the present invention or its salts or suitable complexes is presented as a discreet unit dosage form like a tablet, it may contain in addition medically inert excipients as are used in the art. Diluents such as starch, lactose, dicalcium s phosphate, talc, magnesium stearate, polymeric substances like methyl cellulose, fatty acids and derivatives, sodium starch glycollate, etc. may also be used.
Example 18 Preparation of oral dosage form:
A typical tablet has the following composition:
to Active ingredient of formula I as given above Lactose 13 5 mg Starch 7b mg is Polyvinyl pyrolidone (K-30) 2 mg Talc ~ 1. S mg Magnesium Stearate 1.0 mg Parenteral Formulations For parenteral administration, the compounds or their salts or suitable complexes thereof may be present in a sterile vehicle which may be an aqueous or non aqueous vehicle or a combination thereof. The examples of vehicles are as water, ethyl oleate, oils and derivatives of polyols, glycols and their derivatives. It may contain additives common in injectable preparations like stabilizers, solubilizers, pH modifiers, buffers, antioxidants, cosolvents, complexing agents, tonicity modifiers, etc.
s Some suitable additives are for example tartrate, citrate or similar buffers, alcohol, sodium chloride, dextrose and high molecular weight polymers. Another alternative is sterile powder reconstitution. The compound may be administered in the form of injection for more than once daily administration, or intravenous infusion/ drip or suitable depot preparation.
to Eaamule 19 Preparation suitable for narenteral administration has the following comuosition:
Actlve mgredlent of formula I as given above Polyethylene glycol (400) 0.7 S ml is Sodium metabisulphite 0.01%
Isotonic saline/ WFI q.s.
Other Formnlarions.
For the dermatological application and for the discoloration of teeth, the recommended formulations are lotions, oral rinse and toothpaste containing 2o appropriate amount of the compounds of general formula I.
The above examples are presented by way of illustration alone and in no way limit the scope of the invention.
2b
is 12. OD (optical density) at (450nm reading - 620nm reading) was measured after incubation at 37°C for 15 minutes with Microplate ELISA Reader.
The breaker activity of the compounds were detenmined by the following formula:
Breaker activity = OD4~ZOControl - OD45o.62oTest Zo _~_~~~_~_____~~______ _ x 100 OD 450.20 Control OD4so.~zoControl=Absorbance of 20ng AGE-BSA after incubation at 37°C
for 24 hours without test compound i3 s OD4so.~2oTest=Absorbance of 20ng AGE-BSA after incubation at 37°C for hours with required concentration of test compound Using specific examples, the % AGE breaking activity was calculated and recorded in Table 2.
Table 2 Sample Concentration %Breakage PTB 10 mM 27 20 mM 47 Compound 3 10 mM 5 Compound 4 10 mM 3 Compound 6 10 mM 43 Compound 9 T 10 mM 50 Compound 12 10 mM 57 Compound 13 10 mM 27 Compound 14 20 mM 48 Compound 17 5 mM 45 Compound 18 20 mM 36 to s Hence, for example, compound 12 has significant AGE - breaking activity i.e.
a comparatively much superior potency vis - a - vis PTB.
The following examples give method for preparation of the specific compounds of the invention as given in Table 1. The following compounds suggested are by way of example alone and in no way restrict the invention.
to Example 2 Preparation of 3- carbonvlamino -1- (2- (2,4-dichlorouhenyl) -Z- oxoethvl) pyridinium bromide (comuound 1) Nicotinamide (1.228, O.Oi mol) was dissolved in refluxing toluene (40 ml) and a solution of 2,4-dichlorophenacyl bromide (3.Og, 0.012moI) in 14m1 of is toluene was added. The reaction mixtwre was refluxed for 7.5 hours and cooled.
The precipitated solid was filtered and dissolved in methanol, decolourized with activated charcoal and concentrated under vacuum to one-fourth volume. It was cooled in ice - salt mixture and the precipitated solid was filtered and washed with methanol (3x10m1) to afford a pure solid.
2o Yield : 39%
m.p. : 237-239°C
IR(KBr,clri 1) : 3331, 3133, 1706, i6?8 1H NMR (DMS4d6, 400 MHz) 8 : 9.54(lH,s), 9.18-9.11(ZH,m), 8.67(lH,s), 8.40(lH,t), 8.42-8.38(2H,m), 7.88(lH,s), 7.75 -7.72(lH,m), 6.49(2H,s) s Mass (m/z): 309,310,311,312,187,159 According to the above mentioned procedure the following compounds are synthesized by reacting the corresponding pyridine derivatives with appropriate reagents by refluxing in alcoholic solvents like methanol, ethanol, propanol, etc.
and high boiling solvents like toluene or xylene for 6-48 hours to give the desired to compounds:
Eaamule 3 3-(Tetrahvdrobenzothiazol-2-vl)aminocarbonylY 1-(2-(2,4-dichloropheny,~,l~2-ogoethyl) uyridinium bromide (comuound 2):
Yield : 48%
is m.p. : 165 -167 °C(decomp.) IR(KBr,cni 1) : 3333, 1714, 1684, 1635 1H NMR(CD30D, 400MHz) 8: 9.45(IH,s), 9.27-9.24(lH,m), 8.92-8.91(1H, m), 8.24 - 8.21(1H, m), 8.01 - 7.99(1H, m), 7.72 - 7.71(1H, m) 7.57-7.54(lH,m), 2.59-2.57 (4H,m), 1.85(4H,m) ao Mass (m/z) : 446, 447, 448, 449, 416, 307 and 266 Ezamule 4 1-(2- Phenyl -2- ozoethyl) -3- ((2- hydrogyethyl) aminocarbonvl) pyridinium bromide (comuound 3):
Yield : 98%
s m.p. : 182 - 184°C(decomp.) IR(KBr,clii 1) : 3289, 3241, 1690 and 1660 1H NMR(DMSOd6, 400MHz) 8: 9.47(lH,s), 9.21(lH,t), 9.09(2H,t), 8.41-8.37(lH,m), 8.08-8.04(2H,m), 7.82-7.78(lH,m), 7.69-7.65(2H,m), 6.52(2H,s), 4.86(lH,t), 3.58-3.54(2H,m), 3.42-3.38(2H,m) to Mass (m/z) : 285,242,149,1 I 9,91 Example 5 3-Carbonylamino-1- (2-thien-2'-yl-2-oxoethvl) nyridinium bromide compound 4 ).
Yield : 35%
is m.p. : 212 - 215°C (decomp.) IR(KBr,cni 1) : 3295, 3126, 1680, 1671, 1640 1H NMR (DMSOd6, 400 MHz) 8: 9.49(IH,s), 9.13-9.11(lH,d), 9.07-9.05(lH,d), 8.60(lH,bs), 8.40-8.38(lH,m), 8.25-8.19(3H,m),7.43-7.40,(lH,t), 6.44(2H,s) Mass(m/z) : 247,248,249,193 2o Examine 6 1- (2-Phenyl -2- oxoethyl) -3- ((u-sulfonamidophenylene) aminocarbonYl) pyridinium bromide (comuound 5):
Yield : 44%
m.p. : 188-190°C
s IR(KBr,ctri') : 3296, 1700, 1679.
1H NMR (DMSOd~, 400MHz) S: 11.25 (lH,s), 9.58 (lH,s), 925 (lH,d), 9.16 (1H, d), 8.45 (lH,t), 8.10 (2H,d), 7.94 (2H,d), 7.86 (2H,d), 7.82(lH,t), 7.68(2H,t), 7.36(2H,s), 6.5(2H,s) Mass (m/z) : 396, 277 to Example 7 1- (2- Ethoay -2- oxoethyl) -3- ((2- hydroayethvhocarbonyl) uvrid, i~n~'um bromide compound 6):
Yield : 87%
m.p. : 138-140°C
is IR(KBr, cni ~) : 1748,1669 ~H NMR {CD30D, 400 MHz) 8: 9.43 (lH,s), 9.09-9.02 (2H,ln), 8.26 (lH,m), 5.64 (2H,s), 4.31 (2H,~, 3.73 (2H,t), 3.54 {2H,t}, 1.32 (3H,t) Mass (m/z) : 251, 252, 165, 166 Example 8 Zo 1- (2- Phenyl -2- oxoethvl) -3- (isoprouyloxycarbonvl) uvridinium bromide (compound 7):
Yield : 46%
m.p. : 172-174°C
IR(KBr, cm 1) : 1726, 1692 s 'H NMR (DMSOd6, 400MHz) 8: 9.55 (lH,s), 9.16 (lH,d), 9.08(lH,d), 8.39-8.36 (lH,m), 8.04 (2H,d), 7.77 (lH,t), 7.64 (2H,t), 6.53 (2H,s), 5.25-5.19 (lH,m), 1.34 (6H,d) Mass (m/z) : 284, 285, 242 Example 9 l0 1- (2- Methyl-2-oxoethyl) -3- ((2- hydroxyethvl) aminocarbonvl) pyridinium chloride (compound 8):
Yield : 47%
m.p. : 178-180°C
IR(KBr, clri') : 1727, 1660 is 1H NMR (DMSOdb, 400 MHz) S: 9.33 (lH,t), 9.30 (iH,s), 9.06(lH,d), 8.90 (lH,d), 8.25-8.21 (lH,m), 5.75 (2H,s), 4.84(lH,bs), 3.47 (2H,t), 3.30 (2H,t), 2.23 (3H,s) Mass (m/z) : 223, 224, 225 Example 10 20 1- (2- Thien -2'-yl -2- oxoethyl) -3- ((2- hvdroxyethvly aminocarbonyl~
pyridinium bromide (compound 9):
Yield : 60%
m.p. : 207-209°C
IR(KBr, czri ~) : 1673, 1656 s 1H NMR (DMSOd6, 400MHz} 8: 9.47 (lH,s}, 9.18-9.05 (3H,m),8.38-8.34 (lH,m), 8.23-8.19 (2H,m), 7.39 (lH,t), 6.44 (2H,s),3.55-3.50 (2H,m), 3.40-3.37 (2H,m) Mass (m/z) : 291, 292, 293 Eaample 11 l0 1- (2- (2,4- Dichloronhenyly -2- ozoethyl) -3- (isouropyloaycarbonvl) ~yridinium bromide (comuound 101:
Yield : 26%
m.p. : 160-162°C
is IR (KBr, cm 1) : 1726, 1705 1H NMR (DMSOdb, 400 MHz) 8: 9.55 (lH,s}, 9.15 (lH,d), 9.08(lH,d), 8.40-8.36 (lH,m), 8.11 (lH,d), 7.89 (lH,bs), 7.75-7.72 (lH,m), 6.44 (2H,s), 5.26-5.20 (lH,m), 1.34 (6H,d).
Mass (m/z) : 352, 353, 354, 310 2o Eaamule 12 1- (2- Phenyl -2- oaoethyl) -3- ((4- methylthiazol -2- yl) aminocarb pvridinium bromide (compound 11):
Yield : 30%
m.p. : 165-167°C
s IR (KBr, clri I) : 3409, 3319 and 1698 1H NMR (DMSOd6, 400 MHz) 8: 9.58 (lH,s), 9.22 (lH,d), 9.11(lH,d), 8.42-8.38 (lH,m), 8.07 (2H,d), 7.81 (lH,t), 7.68(2H,t), 6.86 (lH,bs), 6.56 (2H,s), 2.30 (3H,s) Mass (m/z) : 337, 338, 232, 105.
to Example 13 1- (2- Phenylamino -2- oxoethyl) -3- (n- butoxycarbonvl) pyridinium chloride (compound 1 Yield : 10%
m.p. : 150-152°C
is IR (KBr, crri') : 3228, 1742, 1678 (bs) 'H NMR (DMSOd6, 400 MHz) 8: 10.96 (lH,s), 9.65 (lH,s), 9.28(lH,t), 9.09 (lH,d), 8.37 - 8.34 (lH,m), 7.b2 - 7.59 (2H,m),7.37 - 7.33 (2H,m), 7.11 (lH,t), 5.79 (2H,s), 4.41(2H,t), 1.76-1.72(2H,m), 1.48-1.43 (2H,m), 0.94 (3H,t) Mass (m/z) : 314, 3I5 2o Example 14 1- (2- Phenylamino -2- ozoethyl) -3- (n- butvlaminocarbonyl) pyridinium chloride (compound 13):
Yield : 37%
m.p. : 182-185°C
s IR (KBr, clri 1) : 3245, 1742, 1679 'H NMR (DMSOd~, 400MHz) 8: 10.97 (lH,s), 9.50(IH,s), 9.24(lH,t), 9.13 (lH,d), 9.02 (lH,d), 8.28-8.25 (lH,m), 7.57 (2H,d), 7.30(2H,t), 7.05 (lH,t), 5.70 (2H,s), 3.30 - 3.26 (2H,m), 1.52 -1.48 (2H,m), 1.34 -1.30 (2H,m), 0.86 (3H,t) Mass (m/z) : 312, 313 to Example 15 1- (2- Phenylamino -2- oxoethyl) -3- ((2- hvdroavethyl) aminocarbonyl pvridinium chloride (comuound l14 Yield : 58%
m.p. : 225-227°C
is IR (KBr, clri 1) : 3448, 3271, 1702 and 1663 1H NMR (DMSOd6,400 MHz) 8: 11.07 (lH,s), 9.58 (lH,s) 9.35(lH,t), 9.I7 (lH,d), 9.11 (lH,d), 8.33-8.29 (lH,m), 7.60(2H,d), 7.32 (2H,t), 7.08 (lH,t), 5.75 (2H,sj, 4.90 (lH,t), 3.57-3.53 (2H,m), 3.40-3.36 (2H,m) Mass (m!z) : 300, 301, 302 zo Exam lu a 16 1- (2- (2,4- Dichlorophenyl) -2- oxoethvl) -3- (n- butoxycarbonyl) pvridinium bromide (com~round 15):
Yield : 38%
m.p. : 154-156°C
s IR(KBr, clri 1) : 3435, 3389, 1731 and 1704 1H IVMR (DMSOd6, 400 MHz) 8: 9.60 (lH,s), 9.21 (lH,d), 9.14(lH,d), 8.43 (lH,t), 8.16 (lH,d), 7.92 (lH,s), 7.78-7.76(lH,m), 6.51 (2H,s), 4.42 (2H,t), 1.76-1.72 (2H,m), 1.48-1.42 (2H,m), 0.94 (3H,t) Mass (m/z) : 366, 367, 368, 369, 370 to Example 17 1- (2- (2,4- Dichlorophenyl) -2- oxoethyl) -3- (n-butylaminocarbonyl) pyridinium bromide (compound 16):
Yield : 35%
m.p. : 142-144°C
is IR(KBr, clri') : 3382, 1698, 1672 1H NMR (DMSOd6, 400 MHz) 8: 9.37 (lH,s), 9.07 (lH,t), 8.99(2H,t), 8.31-8.28 (lH,m), 8.04 (lH,d) 7.82-7.81 (lH,d), 7.68-7.65 (lH,m), 6.34(2H,s), 3.27-3.24 (2H,m), 1.47-1.43 (2H,m),1.29-1.24 (2H,m), 0.81 (3H,t) Mass (m/z) : 365, 366, 367, 368, 369 2o Pharmaceutical Compositions Pharmaceutical compositions may be prepared with a pharmaceutically effective quantity of compounds of general formula I, individually or in combination. The following pharmaceutical formulations suggested are by way of example alone and in no way restrict the forms in which they can be used.
s Oral formulations Oral formulations may be administered as solid dosage forms for example pellets, powders, sachets or discreet units such as tablets or capsules and like.
Other orally administered pharmaceutical preparations include monophasic and biphasic liquid dosage forms either in ready to use form or forms suitable for to reconstitution such as mixtures, syrups, suspensions or emulsions. The preparations in addition may contain diluents, dispersing agents, buffers, stabilizers, solubilizers, surfactants, preservatives, chelating agents and/
or other pharmaceutical additives as are used. Aqueous or non-aqueous vehicle or their combination may be used and if desired may contain suitable sweetener, flavoring Is agent or similar substances. In case of suspension or emulsion a suitable thickening agent or suspending agent or emulsifying agent may be present in addition. Alternatively, the compounds may be administered as such in their pure form unassociated with other additives for example as capsules or sachets. It may also be administered with a vehicle. Pharmaceutical preparations can have a slow, 2o delayed or controlled release of active ingredients as is provided by a matrix or diffusion controlled system.
When the present invention or its salts or suitable complexes is presented as a discreet unit dosage form like a tablet, it may contain in addition medically inert excipients as are used in the art. Diluents such as starch, lactose, dicalcium s phosphate, talc, magnesium stearate, polymeric substances like methyl cellulose, fatty acids and derivatives, sodium starch glycollate, etc. may also be used.
Example 18 Preparation of oral dosage form:
A typical tablet has the following composition:
to Active ingredient of formula I as given above Lactose 13 5 mg Starch 7b mg is Polyvinyl pyrolidone (K-30) 2 mg Talc ~ 1. S mg Magnesium Stearate 1.0 mg Parenteral Formulations For parenteral administration, the compounds or their salts or suitable complexes thereof may be present in a sterile vehicle which may be an aqueous or non aqueous vehicle or a combination thereof. The examples of vehicles are as water, ethyl oleate, oils and derivatives of polyols, glycols and their derivatives. It may contain additives common in injectable preparations like stabilizers, solubilizers, pH modifiers, buffers, antioxidants, cosolvents, complexing agents, tonicity modifiers, etc.
s Some suitable additives are for example tartrate, citrate or similar buffers, alcohol, sodium chloride, dextrose and high molecular weight polymers. Another alternative is sterile powder reconstitution. The compound may be administered in the form of injection for more than once daily administration, or intravenous infusion/ drip or suitable depot preparation.
to Eaamule 19 Preparation suitable for narenteral administration has the following comuosition:
Actlve mgredlent of formula I as given above Polyethylene glycol (400) 0.7 S ml is Sodium metabisulphite 0.01%
Isotonic saline/ WFI q.s.
Other Formnlarions.
For the dermatological application and for the discoloration of teeth, the recommended formulations are lotions, oral rinse and toothpaste containing 2o appropriate amount of the compounds of general formula I.
The above examples are presented by way of illustration alone and in no way limit the scope of the invention.
2b
Claims (19)
1. A compound of pyridinium series of general formula I and its pharmaceutically acceptable salts, useful for the management of vascular complications associated with diabetes and aging-related disorders, wherein R1 is -Y-R3 Y is selected from oxygen or NH.
R3 is selected from hydrogen, alkyl, aryl R2 is selected from group consisting of alkyl, -Oalkyl, aryl, -Oaryl, -NHalkyl and -NHaryl X is selected from group consisting of a halide ion, acetate ion, perchlorate ion, sulfonate ion, oxalate ion, citrate ion, tosylate ion, maleate ion, mesylate ion, carbonate ion, sulfite ion, phosphoric hydrogen ion, phosphonate ion, phosphate ion, BF4, PF6, with proviso that, (a) when R1 is phenyl then R2 is also phenyl, and (b) when R2 is phenyl and X is a halide ion, R1 is other than -OCH3.
R3 is selected from hydrogen, alkyl, aryl R2 is selected from group consisting of alkyl, -Oalkyl, aryl, -Oaryl, -NHalkyl and -NHaryl X is selected from group consisting of a halide ion, acetate ion, perchlorate ion, sulfonate ion, oxalate ion, citrate ion, tosylate ion, maleate ion, mesylate ion, carbonate ion, sulfite ion, phosphoric hydrogen ion, phosphonate ion, phosphate ion, BF4, PF6, with proviso that, (a) when R1 is phenyl then R2 is also phenyl, and (b) when R2 is phenyl and X is a halide ion, R1 is other than -OCH3.
2. The compound as claimed in claim 1, wherein X is a halide ion.
3. The compound as claimed in claim 1, which is selected from the group consisting of the following compounds:
a) 1-(2-phenylamino-2-oxoethyl)-3-(n-butyloxycarbonyl) pyridinium chloride or a pharmaceutically acceptable salt thereof.
b) 1-(2-thien-2'-yl-2-oxoethyl)-3-((2-hydroxyethyl) aminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
c) 1-(2-ethoxy-2-oxoethyl)-3-((2-hydroxyethyl) aminocarbonyl) pyridinium bromide or a pharmaceutically acceptable salt thereof.
d) 1-(2-phenylamino-2-oxoethyl)-3-(n-butylaminocarbonyl) pyridinium chloride or a pharmaceutically acceptable salt thereof.
e)1-(2-phenylamino-2-oxoethyl)-3-((2-hydroxyethyl) aminocarbonyl)pyridinium chloride or a pharmaceutically acceptable salt thereof.
f) 1-(2-phenyl-2-oxoethyl)-3-((2-hydroxyethyl)aminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
g) 1-(2-methyl-2-oxoethyl)-3-((2-hydroxyethyl) aminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
h) 1-(2-phenyl-2-oxoethyl)-3-((4-methylthiazol-2-yl) aminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
i) 1-(2-(2,4-dichlorophenyl-2-oxoethyl)-3-(isopropyloxycarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
j) 3-(tetrahydrobenzothiazol-2-yl)aminocarbonyl)-1-(2-(2,4-dichlorophenyl)-2-oxoethyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
k) 1-(2-phenyl-2-oxoethyl)-3-((p-sulfonamidophenylene)aminocarbonyl)) pyridinium bromide or a pharmaceutically acceptable salt thereof.
1)3-carbonylamino-1-(2-thien-2'-yl-2-oxoethyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
m) 1-(2-(2,4-dichlorophenyl)2-oxoethyl)-3-(n-butylaminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
n) 1-(2-(2,4-dichlorophenyl)2-oxoethyl)-3-(n-butoxycarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
a) 1-(2-phenylamino-2-oxoethyl)-3-(n-butyloxycarbonyl) pyridinium chloride or a pharmaceutically acceptable salt thereof.
b) 1-(2-thien-2'-yl-2-oxoethyl)-3-((2-hydroxyethyl) aminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
c) 1-(2-ethoxy-2-oxoethyl)-3-((2-hydroxyethyl) aminocarbonyl) pyridinium bromide or a pharmaceutically acceptable salt thereof.
d) 1-(2-phenylamino-2-oxoethyl)-3-(n-butylaminocarbonyl) pyridinium chloride or a pharmaceutically acceptable salt thereof.
e)1-(2-phenylamino-2-oxoethyl)-3-((2-hydroxyethyl) aminocarbonyl)pyridinium chloride or a pharmaceutically acceptable salt thereof.
f) 1-(2-phenyl-2-oxoethyl)-3-((2-hydroxyethyl)aminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
g) 1-(2-methyl-2-oxoethyl)-3-((2-hydroxyethyl) aminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
h) 1-(2-phenyl-2-oxoethyl)-3-((4-methylthiazol-2-yl) aminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
i) 1-(2-(2,4-dichlorophenyl-2-oxoethyl)-3-(isopropyloxycarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
j) 3-(tetrahydrobenzothiazol-2-yl)aminocarbonyl)-1-(2-(2,4-dichlorophenyl)-2-oxoethyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
k) 1-(2-phenyl-2-oxoethyl)-3-((p-sulfonamidophenylene)aminocarbonyl)) pyridinium bromide or a pharmaceutically acceptable salt thereof.
1)3-carbonylamino-1-(2-thien-2'-yl-2-oxoethyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
m) 1-(2-(2,4-dichlorophenyl)2-oxoethyl)-3-(n-butylaminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
n) 1-(2-(2,4-dichlorophenyl)2-oxoethyl)-3-(n-butoxycarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
4. A process for the preparation of compounds of the pyridinium series as claimed in claim 1, wherein said process comprises preparation of the properly substituted pyridine derivatives according to the desired end products followed by quaternization of the substituted pyridine derivatives with appropriate reagent by refluxing in alcoholic solvents and/or high boiling solvents for 6 to 48 hrs. to give the desired compounds.
5. The use of a compound of general formula I as defined in claim 1, in the manufacture of a medicament for diabetic complications and aging-related diseases, including kidney disease, nerve damage, retinopathy, atherosclerosis, microangiopathy, endothelial dysfunctions, dermatological conditions, discoloration of teeth and other organ dysfunctions.
6. The use as claimed in claim 5, wherein said compound is selected from the group consisting of:
a) 1-(2-phenylamino-2-oxoethyl)-3-(n-butyloxycarbonyl) pyridinium chloride or a pharmaceutically acceptable salt thereof.
b) 1-(2-thien-2'-yl-2-oxoethyl)-3-((2-hydroxyethyl) aminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
c) 1-(2-ethoxy-2-oxoethyl)-3-((2-hydroxyethyl) aminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
d) 1-(2-phenylamino-2-oxoethyl)-3-(n-butylaminocarbonyl) pyridinium chloride or a pharmaceutically acceptable salt thereof.
e) 1-(2-phenylamino-2-oxoethyl)-3-((2-hydroxyethyl)aminocarbonyl) pyridinium chloride or a pharmaceutically acceptable salt thereof.
f) 1-(2-phenyl-2-oxoethyl)-3-((2-hydroxyethyl) aminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
g) 1-(2-methyl-2-oxoethyl)-3-((2-hydroxyethyl) aminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
h) 1-(2-phenyl-2-oxoethyl)-3-((4-methylthiazol-2-yl) aminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
i) 1-(2-(2,4-dichlorophenyl-2-oxoethyl)-3-(isopropyloxycarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
j) 3-(tetrahydrobenzothiazol-2-yl)aminocarbonyl-1-(2-(2,4-dichlorophenyl)-2-oxoethyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
k) 1-(2-phenyl-2-oxoethyl)-3-((p-sulfonamidophenylene)aminocarbonyl) pyridinium bromide or a pharmaceutically acceptable salt thereof.
l) 3-carbonylamino-1-(2-thien-2'-yl-2-oxoethyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
m) 1-(2-(2,4-dichlorophenyl)-2-oxoethyl)-3-(n-butylaminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
n) 1-(2-(2,4-dichlorophenyl)-2-oxoethyl)-3-(n-butoxy carbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
a) 1-(2-phenylamino-2-oxoethyl)-3-(n-butyloxycarbonyl) pyridinium chloride or a pharmaceutically acceptable salt thereof.
b) 1-(2-thien-2'-yl-2-oxoethyl)-3-((2-hydroxyethyl) aminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
c) 1-(2-ethoxy-2-oxoethyl)-3-((2-hydroxyethyl) aminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
d) 1-(2-phenylamino-2-oxoethyl)-3-(n-butylaminocarbonyl) pyridinium chloride or a pharmaceutically acceptable salt thereof.
e) 1-(2-phenylamino-2-oxoethyl)-3-((2-hydroxyethyl)aminocarbonyl) pyridinium chloride or a pharmaceutically acceptable salt thereof.
f) 1-(2-phenyl-2-oxoethyl)-3-((2-hydroxyethyl) aminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
g) 1-(2-methyl-2-oxoethyl)-3-((2-hydroxyethyl) aminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
h) 1-(2-phenyl-2-oxoethyl)-3-((4-methylthiazol-2-yl) aminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
i) 1-(2-(2,4-dichlorophenyl-2-oxoethyl)-3-(isopropyloxycarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
j) 3-(tetrahydrobenzothiazol-2-yl)aminocarbonyl-1-(2-(2,4-dichlorophenyl)-2-oxoethyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
k) 1-(2-phenyl-2-oxoethyl)-3-((p-sulfonamidophenylene)aminocarbonyl) pyridinium bromide or a pharmaceutically acceptable salt thereof.
l) 3-carbonylamino-1-(2-thien-2'-yl-2-oxoethyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
m) 1-(2-(2,4-dichlorophenyl)-2-oxoethyl)-3-(n-butylaminocarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
n) 1-(2-(2,4-dichlorophenyl)-2-oxoethyl)-3-(n-butoxy carbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof.
7. The use of 1-(2-phenyl-2-oxoethyl)-3-(1-phenyl-1-oxomethyl)pyridinium bromide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for diabetic complications and ageing related diseases including kidney disease, nerve damage, retinopathy, atherosclerosis, microangiopathy, endothelial dysfunctions, dermatological conditions, discoloration of teeth and other organ dysfunctions.
8. The use of 1-(2-phenyl-2-oxoethyl)-3-(methoxycarbonyl) pyridinium bromide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for diabetic complications and ageing related diseases including kidney disease, nerve damage, retinopathy, atherosclerosis, microangiopathy, endothelial dysfunctions, dermatological conditions, discoloration of teeth and other organ dysfunctions.
9. A pharmaceutical composition for treatment of diabetic complications and aging related diseases which comprises a pharmaceutically effective amount of one or more compounds of general formula I ,as defined in claim 1, or pharmaceutically acceptable salt(s) thereof, in admixture with a pharmaceutically acceptable carrier, diluent, solvent or excepient.
10. The pharmaceutical composition as claimed in claim 9, in the form of an oral formulation.
11. The pharmaceutical composition as claimed in claim 10, wherein the said pharmaceutically acceptable carrier is selected from one or more of the compounds starch, lactose, polyvinylpyrolidone (K-30), talc and magnesium stearate.
12. The pharmaceutical composition as claimed in claim 9, in the form of parenteral formulation.
13. A method for the preparation of a parenteral formulation as claimed in claim 12, which comprises dissolving the active ingredient of general formula I, as defined in claim 1, in polyethylene glycol 400 and diluting the solution so obtained, with an isotonic solution or water to the desired concentration.
14. The pharmaceutical composition as claimed in claim 9, in the form of lotions, oral rinse and toothpaste.
15. A method for treating a diabetic patient by breaking the preformed AGE
within said patient, which comprises administering an effective amount of a compound as claimed in claim 1, either singly or in combination with other drugs for antidiabetic therapy.
within said patient, which comprises administering an effective amount of a compound as claimed in claim 1, either singly or in combination with other drugs for antidiabetic therapy.
16. A method for treating a diabetic patient by breaking the preformed AGE
within said patient which comprises, administering an effective amount of 1-(2-phenyl-2-oxoethyl)-3-(1-phenyl-1-oxomethyl)pyridinium bromide or a pharmaceutically acceptable salt thereof, either singly or in combination with other drugs for antidiabetic therapy.
within said patient which comprises, administering an effective amount of 1-(2-phenyl-2-oxoethyl)-3-(1-phenyl-1-oxomethyl)pyridinium bromide or a pharmaceutically acceptable salt thereof, either singly or in combination with other drugs for antidiabetic therapy.
17. A method for treating a diabetic patient by breaking the preformed AGE, within said patient, which comprises, administering an effective amount of 1-(2-phenyl-2-oxoethyl)-3-(methoxycarbonyl)pyridinium bromide or a pharmaceutically acceptable salt thereof,either singly or in combination with other drugs for antidiabetic therapy.
18. A method of preventing or treating diseases caused by diabetes and aging-related complications, which comprises, administering to a patient in need thereof ,an effective amount of a compound of formula I, as claimed in claim 1, either singly or in combination with a pharmaceutically acceptable carrier, diluent or excepient.
19. The method as claimed in claim 18, wherein the disease caused to be prevented or treated is a nephrological disorder, neurological disorder, atherosclerosis, retinal disorder, dermatological disorder, non-enzymatic browning of oral cavity, endothelial or other organ dysfunction and growth impairment.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN827CA1999 | 1999-10-06 | ||
IN827CAL99 | 1999-10-06 | ||
PCT/IB1999/001687 WO2001025209A1 (en) | 1999-10-06 | 1999-10-15 | Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2351075A1 true CA2351075A1 (en) | 2001-04-12 |
Family
ID=11084921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002351075A Abandoned CA2351075A1 (en) | 1999-10-06 | 1999-10-15 | Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1220843A1 (en) |
JP (1) | JP2003511370A (en) |
CN (1) | CN1329597A (en) |
AU (1) | AU5994499A (en) |
BR (1) | BR9915962A (en) |
CA (1) | CA2351075A1 (en) |
CZ (1) | CZ20011808A3 (en) |
HK (1) | HK1044336A1 (en) |
HU (1) | HUP0301687A2 (en) |
MX (1) | MXPA02003496A (en) |
PL (1) | PL348049A1 (en) |
WO (1) | WO2001025209A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107438604A (en) * | 2015-04-08 | 2017-12-05 | 托伦特药物有限公司 | New pyridine compounds |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA03005954A (en) * | 2000-12-29 | 2004-05-24 | Alteon Inc | Method for treating fibrotic diseases or other indications iiic. |
ES2243389T3 (en) * | 2001-03-21 | 2005-12-01 | Torrent Pharmaceuticals Ltd | PIRIDINUM COMPOUNDS USEFUL FOR THE TREATMENT OF AGE-RELATED DISEASES. |
CZ303214B6 (en) * | 2001-03-21 | 2012-05-30 | Torrent Pharmaceuticals Ltd | Pyridinium compound, process of its preparation, its use, pharmaceutical composition in which it is comprised and use thereof |
WO2002085897A1 (en) * | 2001-04-05 | 2002-10-31 | Alangudi Sankaranarayanan | Heterocyclic compounds for aging-related and diabetic vascular complications |
HUP0104831A2 (en) * | 2001-10-19 | 2003-08-28 | Torrent Pharmaceuticals Ltd. | Composition and method for use of pyridinium derivatives in therapeutic applications |
GB0328314D0 (en) * | 2003-12-05 | 2004-01-07 | Univ Bath | Therapeutics |
WO2007132179A2 (en) * | 2006-05-15 | 2007-11-22 | University Of Bath | Therapeutics comprising pyridinium derivatives |
JP2009155315A (en) * | 2007-12-26 | 2009-07-16 | Fujiyakuhin Co Ltd | Injection product |
EA201171368A1 (en) * | 2009-05-07 | 2012-04-30 | Торрент Фармасьютикалз Лимитед | NEW HETEROCYCLIC COMPOUNDS |
CN110526864A (en) * | 2012-10-05 | 2019-12-03 | 斯菲拉制药私人有限公司 | New compound, its synthesis and application thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH335521A (en) * | 1955-06-02 | 1959-01-15 | Cilag Ag | Process for the preparation of new quaternary salts |
US3318787A (en) * | 1964-02-07 | 1967-05-09 | Udylite Corp | Electrodeposition of zinc |
US3823076A (en) * | 1972-05-23 | 1974-07-09 | Du Pont | Zinc electroplating additive |
JPS5936247B2 (en) * | 1977-04-20 | 1984-09-03 | ティーディーケイ株式会社 | electrical display device |
JPS55138742A (en) * | 1979-04-17 | 1980-10-29 | Fuji Photo Film Co Ltd | Silver halide emulsion developing method |
JPH0253759A (en) * | 1988-08-18 | 1990-02-22 | Hamari Yakuhin Kogyo Kk | Novel quaternary ammonium compound |
DD275872A1 (en) * | 1988-09-27 | 1990-02-07 | Univ Dresden Tech | PROCESS FOR PREPARING 5H-PYRIDO [1 ', 2': 1,2] IMIDAZO [5,4-C] CHINOLIN-6-ONEN |
EP0808163B1 (en) * | 1995-01-18 | 2003-07-23 | Alteon, Inc. | Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts |
WO1998044925A1 (en) * | 1997-04-04 | 1998-10-15 | Smithkline Beecham Corporation | Calcilytic compounds |
-
1999
- 1999-10-15 MX MXPA02003496A patent/MXPA02003496A/en unknown
- 1999-10-15 WO PCT/IB1999/001687 patent/WO2001025209A1/en not_active Application Discontinuation
- 1999-10-15 BR BR9915962-7A patent/BR9915962A/en not_active IP Right Cessation
- 1999-10-15 CZ CZ20011808A patent/CZ20011808A3/en unknown
- 1999-10-15 AU AU59944/99A patent/AU5994499A/en not_active Abandoned
- 1999-10-15 JP JP2001528155A patent/JP2003511370A/en active Pending
- 1999-10-15 PL PL99348049A patent/PL348049A1/en not_active Application Discontinuation
- 1999-10-15 HU HU0301687A patent/HUP0301687A2/en unknown
- 1999-10-15 CA CA002351075A patent/CA2351075A1/en not_active Abandoned
- 1999-10-15 CN CN99814055A patent/CN1329597A/en active Pending
- 1999-10-15 EP EP99974071A patent/EP1220843A1/en not_active Withdrawn
-
2002
- 2002-08-12 HK HK02105890.8A patent/HK1044336A1/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107438604A (en) * | 2015-04-08 | 2017-12-05 | 托伦特药物有限公司 | New pyridine compounds |
CN107438604B (en) * | 2015-04-08 | 2021-12-03 | 托伦特药物有限公司 | Novel pyridine compound |
Also Published As
Publication number | Publication date |
---|---|
MXPA02003496A (en) | 2005-06-20 |
BR9915962A (en) | 2003-01-07 |
WO2001025209A1 (en) | 2001-04-12 |
EP1220843A1 (en) | 2002-07-10 |
HK1044336A1 (en) | 2002-10-18 |
JP2003511370A (en) | 2003-03-25 |
AU5994499A (en) | 2001-05-10 |
CZ20011808A3 (en) | 2001-08-15 |
HUP0301687A2 (en) | 2003-08-28 |
PL348049A1 (en) | 2002-05-06 |
CN1329597A (en) | 2002-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6624178B2 (en) | Compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | |
AU779096B2 (en) | N-(2-hydroxy-3-(1-piperidinyl)propoxy)pyridine-1-oxide-3- carboximidoyl chloride and its use in the treatment of insulin resistance | |
CZ20032013A3 (en) | Heterocyclic compounds intended for treating vascular complications and complications connected with age | |
CA2351075A1 (en) | Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications | |
JPH0832687B2 (en) | 2,4- and 2,5-substituted pyridine-N-oxides | |
US20030203877A1 (en) | Novel post-amadori inhibitors of advanced glycation reactions | |
US6608094B2 (en) | Compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | |
AU2017204652B2 (en) | Treatment of Type I and Type II diabetes | |
EP1243581B1 (en) | Pyridinium compounds useful for the treatment of AGE-related diseases | |
JPH10507446A (en) | Bis-2-aminopyridines, methods for their production and their use for controlling parasite infection | |
JPH10101566A (en) | Medicine for protecting retina | |
US20010018524A1 (en) | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | |
JPH03261772A (en) | Thiazolidine compound and glycation inhibitor containing the same | |
AU3137601A (en) | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses | |
NZ626495B2 (en) | Treatment of type i and type ii diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |